Phase III Multi-Institutional Trial of Adjuvant Chemotherapy With Paclitaxel, Estramustine, and Oral Etoposide Combined With Long-Term Androgen Suppression Therapy and Radiotherapy Versus Long-Term Androgen Suppression Plus Radiotherapy Alone for High-Risk Prostate Cancer: Preliminary Toxicity Analysis of RTOG 99-02-Reference-Cited by-同舟云学术

Phase III Multi-Institutional Trial of Adjuvant Chemotherapy With Paclitaxel, Estramustine, and Oral Etoposide Combined With Long-Term Androgen Suppression Therapy and Radiotherapy Versus Long-Term Androgen Suppression Plus Radiotherapy Alone for High-Risk Prostate Cancer: Preliminary Toxicity Analysis of RTOG 99-02

Published:2009-03 Issue:3 Volume:73 Page:672-678
ISSN:0360-3016
Container-title:International Journal of Radiation Oncology*Biology*Physics
language:en
Short-container-title:International Journal of Radiation Oncology*Biology*Physics

Author:

Rosenthal Seth A.,Bae Kyoungwha,Pienta Kenneth J.,Sobczak Mark L.,Asbell Sucha O.,Rajan Raghu,Kerlin Kevin J.,Michalski Jeff M.,Sandler Howard M.

Publisher

Elsevier BV

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Radiation

Reference18 articles.

1. Cancer statistics, 2008;Jemal;CA Cancer J Clin,2008

2. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer;D'Amico;J Clin Oncol,1999

3. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—Long-term results of phase III RTOG 85-31;Pilepich;Int J Radiat Oncol Biol Phys,2005

4. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin;Bolla;N Engl J Med,1997

5. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomized trial;Bolla;Lancet,2002

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoplasms of the Prostate;Holland‐Frei Cancer Medicine;2022-10-21

2. Indications et perspectives de l’hormonoradiothérapie des cancers de prostate à haut risque;Cancer/Radiothérapie;2020-04

3. Reply to J.B. Aragon-Ching;Journal of Clinical Oncology;2019-09-01

4. Adjuvant Chemotherapy for High-Risk Localized Prostate Cancer: Time for Change or Need More Time to Change?;Journal of Clinical Oncology;2019-09-01

5. Optimisation du contrôle local des cancers de la prostate à haut risque par les traitements multimodaux;Progrès en Urologie;2019-06